Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

insulin (human)

Alternative Names: insulin (human), insulin human, afrezza, ultratard, insuman, insuline umane, insulin isophane, humulin 70/30, humulin r u-500, myxredlin, novolin 70/30, novolin r, humulin n, humulin r, humulin r u-500 kwikpen, humulin 70/30 kwikpen, velosulin, monotard, humulin, insulatard, insulin human, afrezza, ultratard, insuman, insuline umane, insulin isophane, humulin 70/30, humulin r u-500, myxredlin, novolin 70/30, novolin r, humulin n, humulin r, humulin r u-500 kwikpen, humulin 70/30 kwikpen, velosulin, monotard, humulin, insulatard, insulin (human)
Latest Update: 2025-05-14
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: N/A

Route of Administration: Subcutaneous,Intravenous,Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: Tobacco Use Disorder | Acidosis | Diabetic Ketoacidosis | General Diabetes

Known Adverse Events: None

Company: Mannkind
Company Location: WESTLAKE VILLAGE CA 91362
Company CEO: Michael E. Castagna
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for insulin (human)

Countries in Clinic: Austria, Belgium, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Diabetes, Gestational|Hyperglycemia|Other|Type 1 Diabetes|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2023-510358-17-00

P3

Not yet recruiting

Hyperglycemia

2029-06-30

LEVPS

P3

Not yet recruiting

Other

2025-10-15

GPPAD-POInT (Global Platform of Autoimmune Diabetes – Primary Oral Insulin Trial)

P2

Active, not recruiting

Type 1 Diabetes

2025-01-30

INHALE-1

P3

Completed

Type 2 Diabetes|Type 1 Diabetes

2024-10-03

55%
SUGAR-DIP

P3

Completed

Diabetes, Gestational

2023-04-02

Fr1da Insulin Intervention

P2

Completed

Type 1 Diabetes

2024-09-30

ARE-278-104

P1

Completed

Type 2 Diabetes

2024-01-18

4%

Recent News Events

Date

Type

Title

03/10/2025

News Article

 MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

12/16/2024

News Article

 MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

09/30/2024

News Article

 More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)

06/05/2024

News Article

 Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions